Overview of Tuscalman A
Tuscalman A is a fixed-dose combination medication specifically defined by its dual action as an Expectorant and Antitussive Combination. This product is formulated to manage respiratory discomfort by simultaneously addressing both the accumulation of thick mucus and the intensity of the associated cough.
| Property | Description |
|---|---|
| Active Ingredients | Guaifenesin and Noscapine |
| Form | Typically formulated as Suppositories |
| Pharmacological Class | Expectorant and Antitussive Combination |
| Common Purpose | Symptomatic relief from congested chests and cough |
| Origin | Semi-synthetic (Synthetic Guaifenesin and natural alkaloid Noscapine) |
What Type of Medicine Is Tuscalman A?
Tuscalman A is an established combination product in some global markets, pairing the distinct actions of Guaifenesin and Noscapine. This specific combination is often clinically recognized for its ability to target the dual symptoms of a productive cough—that is, a cough accompanied by thick phlegm.
The expectorant component, Guaifenesin, is included in the U.S. FDA's over-the-counter (OTC) Monograph as a safe and effective expectorant for the symptomatic treatment of colds and stable chronic bronchitis. This component is recognized as useful for helping to loosen mucus and thin bronchial secretions.
Composition and Form: Dual Action Ingredients and Suppository Type
The active core features Guaifenesin, a synthetic mucoactive agent, and Noscapine, a centrally acting cough suppressant. Noscapine is a natural alkaloid—specifically a phthalideisoquinoline alkaloid—derived from the opium poppy (Papaver somniferum), although it is classified as a non-narcotic antitussive. This non-narcotic classification indicates that the cough suppression is achieved without the typical addictive properties associated with classical opioid agents.
A defining feature of Tuscalman A is its primary dosage form as suppositories, a solid preparation requiring rectal administration. This formulation method provides an alternative route of drug delivery when oral intake is contraindicated or difficult, contrasting with most common expectorant combinations.
The General Purpose of This Combination Therapy
The overall purpose of Tuscalman A is to enhance the patient's ability to clear mucus while controlling the frequency of irritating coughs. By thinning the sticky secretions, Guaifenesin helps prepare the airways for effective clearance. Simultaneously, Noscapine works on the cough center to reduce the intensity and frequency of the cough reflex, promoting comfort and rest for users experiencing significant respiratory congestion.
Regulatory References
